Neuphoria's Stumble: Social Anxiety Drug Fails, Future Uncertain
Update: 2025-10-20
Description
Neuphoria Therapeutics CRASHES! A major clinical trial for its social anxiety drug FAILED, sending stock plummeting 67%. Is this the end? The company halts development, reassesses strategy, and eyes a potential PTSD pivot. Hope rests on a Merck partnership for Alzheimer's, with a possible $450M payout. Can Neuphoria recover from this devastating blow? Find out what's next for the struggling biotech firm.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
